References of "REGINSTER, Jean-Yves"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailGuidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer : an ESCEO position paper
Rizzoli, R; Body, JJ; De Censi, A et al

in Osteoporosis International (2012), 23

Detailed reference viewed: 21 (1 ULg)
Full Text
Peer Reviewed
See detailRelationship between changes in bone mineral density and incidence of fracture with 6 years of Denosumab treatment
Bolognese, MA; Miller, PD; Reginster, Jean-Yves ULg et al

in Arthritis and Rheumatism (2012), 64(S10), 847

Detailed reference viewed: 23 (1 ULg)
Full Text
Peer Reviewed
See detailCorrection of vitamin D insufficiency with the fixed daily combination strontium ranelate 2 g/vitamin D3 1000 IU over 12 months
Rizzoli, R; Dawson-Hughes, B; Kaufman, JM et al

in Arthritis and Rheumatism (2012), 64(S10), 835

Detailed reference viewed: 20 (3 ULg)
Full Text
Peer Reviewed
See detailStrontium ranelate in knee osteoarthritis trial (SEKOIA) : a structural and symptomatic efficacy
Reginster, Jean-Yves ULg; Chapurlat, R; Christiansen, C et al

in Arthritis and Rheumatism (2012), 64(S10), 681

Detailed reference viewed: 50 (1 ULg)
Full Text
Peer Reviewed
See detailClinically meaningful effect of strontium ranelate on knee osteoarthritis symptoms
Bruyère, Olivier ULg; Bellamy, N; Brown, J et al

in Arthritis and Rheumatism (2012), 64(S10), 110

Detailed reference viewed: 16 (1 ULg)
Full Text
Peer Reviewed
See detailEffects of Strontium ranelate on knee osteoarthritis pain : a responder analysis
Reginster, Jean-Yves ULg; Chapurlat, R; Bellamy, N et al

in Arthritis and Rheumatism (2012), 64(S10), 110

Detailed reference viewed: 11 (1 ULg)
Full Text
Peer Reviewed
See detailToujours pas facile de faire des vieux os
Reginster, Jean-Yves ULg

in Tempo Médical (2012), 348

Detailed reference viewed: 6 (4 ULg)
Full Text
Peer Reviewed
See detailEconomics in osteoporosis : how can we reconciliate the prescribers and the payer ?
Reginster, Jean-Yves ULg; Hiligsmann, Mickaël ULg

in Osteoporosis International (2012), 23(6), 655-661

Detailed reference viewed: 20 (1 ULg)
Full Text
Peer Reviewed
See detailAntidepressant medications and osteoporosis
Rizzoli, R; Cooper, C; Reginster, Jean-Yves ULg et al

in BONE (2012), 51

Detailed reference viewed: 8 (1 ULg)
Full Text
Peer Reviewed
See detailFrailty and sarcopenia : definitions and outcome parameters
Cooper, C; Dere, W; Evans, W et al

in Osteoporosis International (2012), 23

Detailed reference viewed: 39 (5 ULg)
Full Text
Peer Reviewed
See detailNew drugs and nutraceuticals in the treatment of osteoarthritis
Henrotin, Yves ULg; Reginster, Jean-Yves ULg

in Cox Gad, Shayne (Ed.) Development of Therapeutic Agents Handbook (2012)

Detailed reference viewed: 71 (14 ULg)
Full Text
Peer Reviewed
See detailRanelato de estroncio : Um tratamentao de primeira linha para a osteoporose pos-menopausica
Reginster, Jean-Yves ULg

in Expert Approaches in Osteoporosis (2012)

Detailed reference viewed: 29 (6 ULg)
Full Text
Peer Reviewed
See detailEfficacy and safety of oral strontium ranelate for the treatment of knee osteoarthritis: rationale and design of randomised, double-blind, placebo-controlled trial.
Cooper, Cyrus; REGINSTER, Jean-Yves ULg; Chapurlat, Roland et al

in Current Medical Research & Opinion (2012), 28(2), 231-9

Abstract Objective: The osteoporosis drug strontium ranelate dissociates bone remodelling processes. It also inhibits subchondral bone resorption and stimulates cartilage matrix formation in vitro ... [more ▼]

Abstract Objective: The osteoporosis drug strontium ranelate dissociates bone remodelling processes. It also inhibits subchondral bone resorption and stimulates cartilage matrix formation in vitro. Exploratory studies in the osteoporosis trials report that strontium ranelate reduces biomarkers of cartilage degradation, and attenuates the progression and clinical symptoms of spinal osteoarthritis, suggesting symptom- and structure-modifying activity in osteoarthritis. We describe the rationale and design of a randomised trial evaluating the efficacy and safety of strontium ranelate in knee osteoarthritis. Research design, methods, and results: This double-blind, placebo-controlled trial (98 centres, 18 countries) includes ambulatory Caucasian men and women aged >/=50 years with primary knee osteoarthritis of the medial tibiofemoral compartment (Kellgren and Lawrence grade 2 or 3), joint space width (JSW) 2.5 to 5 mm, and knee pain on most days in the previous month (intensity >/=40 mm on a visual analogue scale). Patients are randomly allocated to three groups (strontium ranelate 1 or 2 g/day, or placebo). Follow-up is expected to last 3 years. The primary endpoint is radiographic change in JSW from baseline in each group versus placebo. The main clinical secondary endpoint is WOMAC score at the knee. Safety is assessed at every visit. It is estimated that 1600 patients are required to establish statistical significance with power >90% (0.2 mm +/- 10% between-group difference in change in JSW over 3 years). Recruitment started in April 2006. The results are expected in spring 2012. Clinical trial registration: The trial is registered on www.controlled-trials.com (number ISRCTN41323372). Conclusions: This randomised, double blind, placebo-controlled study will establish the potential of strontium ranelate in improving structure and symptoms in patients with knee osteoarthritis. [less ▲]

Detailed reference viewed: 144 (13 ULg)
Full Text
Peer Reviewed
See detailTreatment of postmenopausal women with osteoporosis for six years with denosumab : three-year results from the freedom extension
Chapurlat, R; Papapoulos, S; Brown, JP et al

in Annals of the Rheumatic Diseases (2012), 71(3), 588

Detailed reference viewed: 27 (1 ULg)
Full Text
Peer Reviewed
See detailNominal group technique to prioritize preferences for medication attributes from the patients’ perspective : the case of osteoporosis
Hiligsmann, Mickaël ULg; Van Durme, C; Geusens, P et al

in Annals of the Rheumatic Diseases (2012), 71(3), 597

Detailed reference viewed: 30 (5 ULg)